about
Treatment for POEMS (polyneuropathy, organomegaly, endocrinopathy, M-protein, and skin changes) syndromeTreatment for POEMS (polyneuropathy, organomegaly, endocrinopathy, M-protein, and skin changes) syndromeTreatment for POEMS (polyneuropathy, organomegaly, endocrinopathy, M-protein, and skin changes) syndromeAppraisal of immunoglobulin free light chain as a marker of responseImmunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myelomaMonoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective studySerum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significanceImmunoglobulin free light chains and solitary plasmacytoma of boneImmunoglobulin Light-Chain Amyloidosis: From Basics to New Developments in Diagnosis, Prognosis and TherapySmoldering multiple myeloma requiring treatment: time for a new definition?Phase I trial of autologous hematopoietic SCT with escalating doses of topotecan combined with CY and carboplatin in patients with relapsed or persistent ovarian or primary peritoneal carcinoma.Rationale, application and clinical qualification for NT-proBNP as a surrogate end point in pivotal clinical trials in patients with AL amyloidosisGene-expression profiling of Waldenstrom macroglobulinemia reveals a phenotype more similar to chronic lymphocytic leukemia than multiple myeloma6q deletion discriminates Waldenström macroglobulinemia from IgM monoclonal gammopathy of undetermined significanceDiagnosis and management of Waldenström macroglobulinemia: Mayo stratification of macroglobulinemia and risk-adapted therapy (mSMART) guidelinesMyeloma: management of the newly diagnosed high-risk patient.Improved Outcomes After Autologous Hematopoietic Cell Transplantation for Light Chain Amyloidosis: A Center for International Blood and Marrow Transplant Research StudyImpact of pretransplant therapy and depth of disease response before autologous transplantation for multiple myeloma.Older patients with myeloma derive similar benefit from autologous transplantation.Biologic and genetic characterization of the novel amyloidogenic lambda light chain-secreting human cell lines, ALMC-1 and ALMC-2.Trends in utilization and outcomes of autologous transplantation as early therapy for multiple myeloma.Salvage second hematopoietic cell transplantation in myelomaUtility of Doppler myocardial imaging, cardiac biomarkers, and clonal immunoglobulin genes to assess left ventricular performance and stratify risk following peripheral blood stem cell transplantation in patients with systemic light chain amyloidosiAntithymocyte globulin has limited efficacy and substantial toxicity in unselected anemic patients with myelodysplastic syndrome.Poor tolerance to high doses of thalidomide in patients with primary systemic amyloidosis.Implantable cardioverter defibrillators in patients with cardiac amyloidosis.High-dose samarium-153 ethylene diamine tetramethylene phosphonate: low toxicity of skeletal irradiation in patients with osteosarcoma and bone metastases.Posttransplantation thrombotic thrombocytopenic purpura: a single-center experience and a contemporary review.Prognostic model for disease-specific and overall mortality in newly diagnosed symptomatic patients with Waldenstrom macroglobulinaemia.The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis.Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma.Low risk of symptomatic venous thromboembolic events during growth factor administration for PBSC mobilization.Lenalidomide plus dexamethasone vs. lenalidomide plus melphalan and prednisone: a retrospective study in newly diagnosed elderly myeloma.Clarithromycin (Biaxin)-lenalidomide-low-dose dexamethasone (BiRd) versus lenalidomide-low-dose dexamethasone (Rd) for newly diagnosed myeloma.Pomalidomide (CC4047) plus low dose dexamethasone (Pom/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM).Phase 2 trial of intravenously administered plerixafor for stem cell mobilization in patients with multiple myeloma following lenalidomide-based initial therapy.Phase 2 trial of ixazomib in patients with relapsed multiple myeloma not refractory to bortezomibMutations in specific structural regions of immunoglobulin light chains are associated with free light chain levels in patients with AL amyloidosis.International, evidence-based consensus diagnostic criteria for HHV-8-negative/idiopathic multicentric Castleman disease.Pomalidomide, Bortezomib and Dexamethasone (PVD) for Patients with Relapsed, Lenalidomide Refractory Multiple Myeloma.
P50
Q24202634-18E308BE-2D69-479F-BC92-15AE548C598DQ24241063-54EDD8E1-62B4-46B5-AF84-502E5B7F1028Q24243133-189091C1-22F7-4E00-AB66-9C5981B18864Q24624398-F570DAF2-37F8-4486-9532-93B97C9BE36DQ24650785-F925D2DF-CB2D-44FD-BE4B-AC7196D948D7Q24653006-EE5E57BE-2FDD-4BD9-B645-6D9DD075BABBQ24669898-D5F2E2E2-051A-436D-9AFE-79B820BB6881Q24685868-28E567E1-7627-4281-8C89-201C86555840Q26771690-2B94B682-2A6F-42CF-8C34-F9311050EFC2Q26996579-8E5D0F2D-A741-4F03-9362-C65A45282716Q27851478-0FBA3C3D-1987-42B1-8045-56AB8EE25A6DQ28069975-DC80877C-5647-4350-8F7C-2823624C08C8Q28248800-A467BFBB-09D8-4266-9129-7084DB626F5BQ28260593-62D8EDCD-39E6-4200-9803-C27383F83233Q28290236-BA4F9EBD-74BC-40C9-96A3-A62D80776DA3Q30240403-98A3DAC0-CA6B-4C66-9994-E81DA1EFD083Q30278687-20E7ED62-9EF1-4626-8777-0E93A5882703Q30301228-936E2033-2194-4053-9518-C9D6298C436CQ30370038-A25BE13A-D84C-472B-BBD5-3EBE20CC0D3AQ30370141-67ABD099-E132-43F7-B97D-2658D419BB15Q30409713-8132DF36-2A25-4A0B-B0DE-248C4EFB9BF6Q30416452-8798EC83-2739-44A3-95CB-28E76A76BDEEQ30469018-848E80D2-1186-4142-822A-BA109442D1C8Q33148268-8DD13A89-52A9-4A10-A3C6-6118B5BFAE24Q33151135-34051155-F195-4762-ACBA-B561FA32FB9BQ33162514-7AF747B9-067D-4B51-B303-7235BF2781EEQ33340441-EB010518-AC87-458D-8C94-E9BC39AD8E8FQ33347394-B3BE604D-F838-4627-94C1-7C07208A8C1EQ33370834-89634AD3-10EC-4CD8-A5ED-2EC1F2AB5C8FQ33372805-A8D22C4D-19E2-4DDF-A019-A9D3861DF7CDQ33386052-8DF2E015-3D5E-4771-908E-6062FD18965EQ33389390-CF15813D-D332-468A-8800-F901048473CEQ33389606-B8DFEC34-5043-4504-BB2B-33A5FCABDE51Q33390873-60DBC01B-D470-41D0-868C-28D77902EA6AQ33391803-8EE40DAC-8D99-4738-8D04-FAA394ED613DQ33411277-7929E7B2-1975-4175-8AFC-3046BE237C62Q33425190-62B77AF4-1BC9-4B46-BA4B-9C0C5658C937Q33429992-FFA46870-6128-40A0-8185-685D1F061ED7Q33438403-5EF0F308-B122-4D12-A2F9-70C173A794F4Q33443411-F66D510F-D663-4B94-AD28-9831DBF5E98E
P50
description
hulumtuese
@sq
researcher
@en
ricercatrice
@it
wetenschapper
@nl
հետազոտող
@hy
name
Angela Dispenzieri
@ast
Angela Dispenzieri
@en
Angela Dispenzieri
@es
Angela Dispenzieri
@nl
Angela Dispenzieri
@sl
type
label
Angela Dispenzieri
@ast
Angela Dispenzieri
@en
Angela Dispenzieri
@es
Angela Dispenzieri
@nl
Angela Dispenzieri
@sl
prefLabel
Angela Dispenzieri
@ast
Angela Dispenzieri
@en
Angela Dispenzieri
@es
Angela Dispenzieri
@nl
Angela Dispenzieri
@sl
P214
P106
P108
P1153
7004528670
P21
P214
P31
P496
0000-0001-8780-9512
P735
P7859
viaf-311246599